Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

DF Murrell, S Dick, AR Ahmed, M Amagai… - Journal of the American …, 2008 - Elsevier
Our scientific knowledge of pemphigus has dramatically progressed in recent years.
However, despite the availability of various therapeutic options for the treatment of …

Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis

N Fett, VP Werth - Journal of the American Academy of Dermatology, 2011 - Elsevier
Morphea, also known as localized scleroderma, is a rare fibrosing disorder of the skin and
underlying tissues. Morphea is differentiated from systemic sclerosis based on the absence …

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts

DF Murrell, BS Daniel, P Joly, L Borradori… - Journal of the American …, 2012 - Elsevier
Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent
years. However, despite the availability of various therapeutic options for the treatment of …

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

M Petri, AM Orbai, GS Alarcón, C Gordon… - Arthritis & …, 2012 - Wiley Online Library
Abstract Objective The Systemic Lupus International Collaborating Clinics (SLICC) group
revised and validated the American College of Rheumatology (ACR) systemic lupus …

[PDF][PDF] 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory …

IE Lundberg, A Tjärnlund, M Bottai… - Arthritis & …, 2017 - Wiley Online Library
Objective To develop and validate new classification criteria for adult and juvenile idiopathic
inflammatory myopathies (IIM) and their major subgroups. Methods Candidate variables …

[PDF][PDF] Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus

R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

M Khamashta, JT Merrill, VP Werth, R Furie… - Annals of the …, 2016 - ard.bmj.com
Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb,
randomised, double-blind, placebo-controlled study (NCT01283139) of adults with …

[HTML][HTML] The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus

J Albrecht, L Taylor, JA Berlin, S Dulay, G Ang… - Journal of Investigative …, 2005 - Elsevier
We developed and validated a measurement instrument (CLASI—Cutaneous Lupus
Erythematosus Disease Area and Severity Index) for lupus erythematosus that could be …

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

R Van Vollenhoven, A Voskuyl, G Bertsias… - Annals of the …, 2017 - ard.bmj.com
Objectives Treat-to-target recommendations have identified 'remission'as a target in
systemic lupus erythematosus (SLE), but recognise that there is no universally accepted …

Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (mmt) …

LG Rider, VP Werth, AM Huber… - Arthritis care & …, 2011 - Wiley Online Library
The idiopathic inflammatory myopathies, including adult and juvenile dermatomyositis (DM),
polymyositis (PM), and inclusion body myositis (IBM), are rare systemic autoimmune …